Jacobs Levy Equity Management, Inc Supernus Pharmaceuticals, Inc. Transaction History

Jacobs Levy Equity Management, Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 17, 2021	SELL	$24.15 - $31.45 $16.5 Million - $21.5 Million	-683,835 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$17.7 - $25.81 $2.42 Million - $3.52 Million	136,537 Added 24.95%	683,835 $17.2 Million
Q3 2020 Nov 16, 2020	BUY	$20.2 - $25.05 $1.83 Million - $2.27 Million	90,717 Added 19.87%	547,298 $11.4 Million
Q2 2020 Aug 17, 2020	BUY	$17.09 - $24.89 $6.91 Million - $10.1 Million	404,362 Added 774.36%	456,581 $10.8 Million
Q1 2020 May 15, 2020	BUY	$14.45 - $24.69 $754,564 - $1.29 Million	52,219 New	52,219 $939,000
Q2 2018 Aug 14, 2018	SELL	$44.1 - $59.85 $560,511 - $760,693	-12,710 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$37.15 - $46.9 $472,176 - $596,099	12,710 New	12,710 $582,000

290

60.7M

27.7K

11.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $2.05B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.